WebBivalirudin inhibits both circulating thrombin and fibrin bound thrombin directly by binding to thrombin catalytic site and anion-binding exosite I in a concentration-dependent manner. Bivalirudin prolongs activated partial thromboplastin time, prothrombin time, thrombin time and activated clotting time (ACT). WebFeb 1, 2024 · The major adverse effect of heparin is heparin-induced thrombocytopenia (HIT), a paradox in which an anticoagulant causes a …

Bivalirudin: pharmacology and clinical applications - PubMed

WebBivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI). … Webanticoagulation in HIT.4 Argatroban may be used for prophylaxis, treatment, and also for anticoagulation during percutaneous cardiac intervention (PCI, cardiac catheterization) for patients with HIT.5 The physician initiates the argatroban intravenous infusion at 2 µg/kg/min or in patients with liver disease at 0.5 µg/kg/min. old war teliscopes

Bivalirudin use during radiofrequency catheter ablation …

WebCurrent guidelines recommend using bivalirudin, a direct thrombin inhibitor,as a preferred alternative to unfractionated heparin in patients with heparin induced thrombocytopenia … WebFor HIT, monitoring every 2 to 4 hours until in range and then once daily; for PCI, monitoring is unnecessary unless renal failure is present. Internal laboratory validation demonstrates that plasma concentrations of bivalirudin from 0.25 to 2.00 mcg/mL correspond to an aPTT ratio of 1.5 to 3.0. WebThe incidence of HIT is highest among patients undergoing cardiac surgeries, with a reported incidence of 1–3%, but patients receiving mechanical circulatory support have an even higher incidence at 10.6%. 9, 10 Clinicians are likely to encounter scenarios in which alternative anticoagulation strategies are needed to manage HIT whereas a patient is … is a firefighter a government job